Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 3/20 | 0.83 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.83 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sgs-742 SCHEMBL195133 | 0.91 | GABBR2 (1.00) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL6351264 | 0.88 | GABBR2 (0.87) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| Sgs-742 SCHEMBL6024389 | 0.88 | GABBR2 (0.95) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL6356276 | 0.86 | GABBR2 (0.83) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL6354602 | 0.86 | GABBR2 (0.83) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL6360412 | 0.86 | GABBR2 (0.83) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL6358928 | 0.86 | GABBR2 (0.83) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL2348729 | 0.83 | — | — | |
| SCHEMBL2488286 | 0.82 | GABBR2 (0.70) | GABBR2GABBR1GABRR1 | |
| SCHEMBL6353766 | 0.82 | GABBR2 (0.63) | GABBR2GABBR1GABRR1CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372620-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | Saegis Pharmaceuticals (US) | 2004-01-02 | — | — | EP | claimed |
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | SAEGIS PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | claimed |
| WO-2002074293-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | SAEGIS PHARMACEUTICALS INC (US) | 2002-09-26 | — | — | WO | claimed |
| EP-0319482-B1 | Novel substituted propane phosphinic acid compounds | CIBA GEIGY AG (CH) | 1994-05-18 | — | — | EP | claimed |
| EP-0319479-A2 | Substituted propane-phosphinic acid compounds | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | claimed |
| EP-0319482-A2 | Novel substituted propane phosphinic acid compounds | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | claimed |
| US-9035088-B2 | Method for producing mono-aminofunctionalized dialkylphosphinic acids and esters and salts thereof by means of acrylnitriles and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-05-19 | — | — | US | disclosed |
| CN-102186866-B | Method for producing mono amino-functionalised dialkylphosphinite acids esters and salts and use thereof | CLARIANT INT LTD | 2015-04-29 | — | — | CN | disclosed |
| EP-2373666-B1 | METHOD FOR PRODUCING MONO-AMINOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLNITRILES AND USE THEREOF | CLARIANT FINANCE BVI LTD (VG) | 2014-09-24 | — | — | EP | disclosed |
| US-8604232-B2 | Method for producing monoamino-functionalised dialkylphosphinite acids esters and salts and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2013-12-10 | — | — | US | disclosed |
| EP-2352741-B1 | METHOD FOR PRODUCING MONO AMINO-FUNCTIONALISED DIALKYLPHOSPHINITE ACIDS ESTERS AND SALTS AND USE THEREOF | CLARIANT INT LTD (CH) | 2013-08-28 | — | — | EP | disclosed |
| EP-2373666-A1 | METHOD FOR PRODUCING MONO-AMINOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLNITRILES AND USE THEREOF | Clariant Finance (BVI) Limited (VG) | 2011-10-12 | — | — | EP | disclosed |
| CN-102186866-A | Method for producing mono amino-functionalised dialkylphosphinite acids esters and salts and use thereof | CLARIANT INT LTD | 2011-09-14 | — | — | CN | disclosed |
| US-5300679-A | Antagonists to 4-aminobutyric acid | CIBA-GEIGY CORPORATION (US) | 1994-04-05 | — | — | US | disclosed |
| US-5190933-A | Treatment of cognitive and memory disorders | CIBA-GEIGY CORPORATION (US) | 1993-03-02 | — | — | US | disclosed |
| US-5064819-A | Antidepressants, anxiolytic agents, GABA antagonists | CIBA-GEIGY CORPORATION (US) | 1991-11-12 | — | — | US | disclosed |
| US-5051524-A | Treatment of a phosphinic acid with an anhydrous protic medium | CIBA-GEIGY CORPORATION (US) | 1991-09-24 | — | — | US | disclosed |
| US-5013863-A | Learning enhancement | CIBA-GEIGY CORPORATION (US) | 1991-05-07 | — | — | US | disclosed |
| EP-0319479-A2 | Substituted propane-phosphinic acid compounds | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | disclosed |
| EP-0319482-A2 | Novel substituted propane phosphinic acid compounds | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | CRH, BDNF, CHAT | GABBR2 2093/4885GABBR1 1947/4885GABRR1 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.